NH PHL Discipline A Microbiology Analytical Track 5 capability-capacity development

NH PHL 学科 A 微生物学分析 Track 5 能力-能力发展

• 批准号: 10173074
• 负责人: Christine Louise Bean
• 金额: $ 7.5万
• 依托单位: NH STATE DEPT/HLTH STATISTICS/DATA MGMT
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-09-01 至 2025-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10173074
• 关键词: NH; PHL; Discipline; Microbiology; Analytical

Discipline A: Microbiology Analytical Track 5: Microbiology Capability/Capacity Development To build additional capability and expand the national capacity in microbiological areas of emerging technology where the FDA has identified a specific need. The NH PHL will develop the capability to test for Cyclospora in human food product and environmental samples. The New Hampshire Public Health Laboratories (NH PHL) will purchase appropriate equipment and supplies such as filters, rotary shaker, vacuum manifold, heating block and reagents. The NH PHL has thermocyclers, Dynal bead system, fluorescent microscope and gel electrophoresis systems. Personnel will be trained on the FDA BAM 19b method: Molecular Detection of Cyclospora cayetanensis in Fresh Produce using real-time PCR. Appropriate proficiency testing will be either purchased or developed in-house to demonstrate competency in the newly developed method. NH PHL will participate and pass annual proficiency tests, attend the LFFM Face-to-Face meeting and monthly calls, maintain ISO 17025 accreditation, maintain facilities and personnel necessary to complete the work proposed, and provide a detailed quarterly summary of all samples collected and analyzed. The NH PHL will maintain a valid 20.88 agreement with the FDA.

学科A：微生物学 分析轨道5：微生物学能力/能力发展 建立额外的能力并扩大国家的国家能力 FDA确定了特定需求的新兴技术。 NH PHL将发展 在人类食品和环境样品中测试环孢子虫的能力。 新罕布什尔州公共卫生实验室（NH PHL）将购买适当的设备 以及诸如过滤器，旋转振荡器，真空歧管，加热块和试剂之类的供应。 NH PHL具有热循环器，染色珠系统，荧光显微镜和凝胶电泳 系统。人员将接受FDA BAM 19B方法的培训：分子检测 使用实时PCR，新鲜农产品中的环孢子虫。适当的能力测试 将在内部购买或开发以展示新的能力 开发的方法。 NH PHL将参加并通过年度能力测试，参加LFFM面对面会议 以及每月电话，维护ISO 17025认证，维护必要的设施和人员 要完成提议的工作，并提供收集的所有样本的详细季度摘要 并进行了分析。 NH PHL将与FDA保持有效的20.88协议。